Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Benzyl Benzoate→

Benzyl Benzoate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
120-51-4
Molecular formula
C14H12O2
Molecular weight
212.24 g/mol
Drug class
Topical scabicide and pediculicide (benzyl ester of benzoic acid)
Mechanism of action
A topical acaricidal/pediculicidal agent that is toxic to mites and lice. The exact molecular mechanism in the parasite is not fully characterised in the cited product-use guidance.
Indications / reported uses
  • Topical treatment of scabies
  • Treatment of head, body and pubic lice where an appropriate benzyl-benzoate formulation is authorised; concentration, dilution and contact time are age- and product-specific

Sources: MSF Clinical Guidelines — Benzyl benzoate lotion · Government of India — National Formulary of India (2011), scabicides and pediculicides · WHO EMRO — Benzyl benzoate drug summary · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Benzyl Benzoate Environmental Risk Assessment (ERA) (the Benzyl Benzoate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.